Detalhe da pesquisa
1.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Cancer Immunol Immunother
; 73(4): 72, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430405
2.
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
Bioorg Med Chem
; 28(2): 115227, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31862310
3.
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5.
Blood Adv
; 7(17): 5108-5121, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184294
4.
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Mol Cancer Ther
; 22(10): 1154-1165, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37486983
5.
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Clin Cancer Res
; 28(22): 4871-4884, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36044531
6.
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
NPJ Precis Oncol
; 6(1): 95, 2022 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36575215
7.
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
J Hematol Oncol
; 14(1): 186, 2021 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34742344
8.
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Eur J Cancer
; 146: 115-124, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33601323
9.
3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.
Bioorg Med Chem Lett
; 19(3): 701-5, 2009 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19114305
10.
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
Bioorg Med Chem Lett
; 18(17): 4794-7, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18694641
11.
BRD4 facilitates replication stress-induced DNA damage response.
Oncogene
; 37(28): 3763-3777, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29636547
12.
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
PLoS One
; 13(7): e0200826, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30036377
13.
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.
Cancer Immunol Res
; 6(10): 1234-1245, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30087114
14.
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Mol Cancer Ther
; 15(11): 2563-2574, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27573426